<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04078295</url>
  </required_header>
  <id_info>
    <org_study_id>E7389-J081-120</org_study_id>
    <nct_id>NCT04078295</nct_id>
  </id_info>
  <brief_title>A Study of E7389 Liposomal Formulation (E7389-LF) Plus Nivolumab in Participants With Solid Tumor</brief_title>
  <official_title>An Open-Label Phase 1b/2 Study of E7389 Liposomal Formulation Plus Nivolumab in Subjects With Solid Tumor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eisai Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ono Pharmaceutical Co. Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Eisai Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of the study is to evaluate safety and tolerability and to determine
      recommended Phase 2 dose (RP2D) of E7389-LF in combination with nivolumab in Phase 1b part,
      and to evaluate objective response rate (ORR) of E7389-LF and nivolumab using RP2D in Phase 2
      part in each tumor type.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 5, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase 1b: Number of Participants with Dose Limiting Toxicities (DLTs)</measure>
    <time_frame>Baseline up to Cycle 1 (Cycle length is equal to [=] up to 28 days)</time_frame>
    <description>DLTs are defined as study drug related adverse events (AEs). Toxicity will be evaluated according to National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 (NCI CTCAE 5.0).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 1b: RP2D of E7389-LF in Combination With Nivolumab</measure>
    <time_frame>Up to 12 Months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2: ORR</measure>
    <time_frame>Up to 36 Months</time_frame>
    <description>ORR is defined as the percentage of participants who have best overall response of complete response (CR) or partial response (PR). The ORR will be assessed by investigator based on response evaluation criteria in solid tumors (RECIST) version 1.1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase 1b and Phase 2: Number of Participants With AEs and Serious Adverse Events (SAEs)</measure>
    <time_frame>Up to 30 days after the last dose of study drug or before initiating post anti-cancer treatment, whichever shorter (up to 36 Months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b and Phase 2, Cmax: Maximum Observed Plasma Concentration of E7389-LF</measure>
    <time_frame>Phase 1b, Cycle 1 Day 1: 0 to 24 hours, Cycle 1 Days 4 and 8; Phase 2, Cycle 1 Days 1 and 8 (Cycle length = up to 28 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b and Phase 2: Serum Concentration of Nivolumab</measure>
    <time_frame>Up to 36 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b and Phase 2, Tmax: Time to Maximum Observed Plasma Concentration (Cmax) of E7389-LF</measure>
    <time_frame>Phase 1b, Cycle 1 Day 1: 0 to 24 hours, Cycle 1 Days 4 and 8; Phase 2, Cycle 1 Days 1 and 8 (Cycle length = up to 28 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b and Phase 2, AUC: Area Under the Plasma Concentration-time Curve Over Time From 0 to Last Measurable Concentration of E7389-LF</measure>
    <time_frame>Phase 1b, Cycle 1 Day 1: 0 to 24 hours, Cycle 1 Days 4 and 8; Phase 2, Cycle 1 Days 1 and 8 (Cycle length = up to 28 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b and Phase 2, T1/2: Terminal Phase Elimination Half-life of E7389-LF</measure>
    <time_frame>Phase 1b, Cycle 1 Day 1: 0 to 24 hours, Cycle 1 Days 4 and 8; Phase 2, Cycle 1 Days 1 and 8 (Cycle length = up to 28 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b and Phase 2, CL: Total Body Clearance of E7389-LF</measure>
    <time_frame>Phase 1b, Cycle 1 Day 1: 0 to 24 hours, Cycle 1 Days 4 and 8; Phase 2, Cycle 1 Days 1 and 8 (Cycle length = up to 28 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b and Phase 2, Vd: Volume of Distribution of E7389-LF</measure>
    <time_frame>Phase 1b, Cycle 1 Day 1: 0 to 24 hours, Cycle 1 Days 4 and 8; Phase 2, Cycle 1 Days 1 and 8 (Cycle length = up to 28 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: Progression-Free Survival (PFS)</measure>
    <time_frame>From the first does of the study drug up to the first documentation of disease progression or death due to any cause, whichever comes first (up to 36 Months)</time_frame>
    <description>PFS is defined as the time from the date of the first administration of drug to the date of the first documentation of disease progression or death due to any cause, whichever comes first. The PFS will be assessed by investigator based on RECIST version 1.1.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">116</enrollment>
  <condition>Solid Neoplasms</condition>
  <arm_group>
    <arm_group_label>Phase 1b: E7389-LF + Nivolumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive specified doses of E7389-LF (intravenous) and nivolumab (intravenous) on specified days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2, Cohort-1: E7389-LF + Nivolumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive RP2D of E7389-LF (intravenous) and nivolumab (intravenous) determined in Phase 1b part.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2, Cohort-2: E7389-LF + Nivolumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive RP2D of E7389-LF (intravenous) and nivolumab (intravenous) determined in Phase 1b part.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2, Cohort-3: E7389-LF + Nivolumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive RP2D of E7389-LF (intravenous) and nivolumab (intravenous) determined in Phase 1b part.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>E7389-LF</intervention_name>
    <description>E7389-LF Intravenous infusion.</description>
    <arm_group_label>Phase 1b: E7389-LF + Nivolumab</arm_group_label>
    <arm_group_label>Phase 2, Cohort-1: E7389-LF + Nivolumab</arm_group_label>
    <arm_group_label>Phase 2, Cohort-2: E7389-LF + Nivolumab</arm_group_label>
    <arm_group_label>Phase 2, Cohort-3: E7389-LF + Nivolumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>Nivolumab Intravenous infusion.</description>
    <arm_group_label>Phase 1b: E7389-LF + Nivolumab</arm_group_label>
    <arm_group_label>Phase 2, Cohort-1: E7389-LF + Nivolumab</arm_group_label>
    <arm_group_label>Phase 2, Cohort-2: E7389-LF + Nivolumab</arm_group_label>
    <arm_group_label>Phase 2, Cohort-3: E7389-LF + Nivolumab</arm_group_label>
    <other_name>ONO-4538</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Phase 1b part only: Participants with advanced, nonresectable, or recurrent solid
             tumor for which no alternative standard therapy or no effective therapy exists
             (participants who will be the candidate of treatment by nivolumab monotherapy as
             standard therapy is acceptable)

          2. Phase 2 part only: Nonresectable specific solid tumor participants with confirmed
             diagnosis who showed disease progression by investigator's assessment during or after
             1st line chemotherapy and did not receive any other systemic chemotherapy to
             advanced/recurrent disease

          3. Participants who have accessible tumors for biopsy and agree with tumor biopsy for pre
             and post treatment of study drug (If a pre-treatment biopsy cannot be obtained due to
             safety issue, then an archival tumor tissue sample may be submitted)

          4. Life expectancy of greater than or equal to (&gt;=) 12 weeks

          5. Eastern Cooperative Oncology Group-Performance Status (ECOG-PS) 0-1

          6. Phase 2 part only: At least one measurable lesion based on RECIST 1.1 (Lesions that
             have had radiotherapy or loco-regional therapies must show evidence of progressive
             disease to be deemed a measurable lesion)

        Exclusion Criteria:

          1. Diagnosed with meningeal carcinomatosis

          2. Participants with brain or subdural metastases or invasion are not eligible

          3. Participants with any active, known, or suspected autoimmune disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Inquiry Service</last_name>
    <email>eisai-chiken_hotline@hhc.eisai.co.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>Eisai Trial Site #2</name>
      <address>
        <city>Kashiwa</city>
        <state>Chiba</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Eisai Trial Site #1</name>
      <address>
        <city>Chuo Ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>September 2, 2019</study_first_submitted>
  <study_first_submitted_qc>September 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 6, 2019</study_first_posted>
  <last_update_submitted>April 27, 2020</last_update_submitted>
  <last_update_submitted_qc>April 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>E7389 liposomal formulation</keyword>
  <keyword>Nivolumab</keyword>
  <keyword>Neoplasms</keyword>
  <keyword>Solid Tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Eisai's data sharing commitment and further information on how to request data can be found on our website http://eisaiclinicaltrials.com/.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

